BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge
Much of the investor doubt surrounding Bristol-Myers Squibb’s $ 74 billion Celgene buyout centers on the multiple myeloma blockbuster Revlimid—namely, whether its remaining patents can stand up to legal challenges. But the companies just scored a win in that department. Thursday, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) decided not… Read More »
